

Dopamine agonists in prolactinoma

Table S2. Secondary outcomes

Variable	Number of studies (n)	Estimate, SMD (95% CI)	Difference in mean (95% CI)
Weight	13 (720)	-0.20 (-0.36 to -0.05; p = 0.01; I ² = 71%)	
BMI	12 (690)	-0.22 (-0.38 to -0.05; p = 0.01; I ² = 73%)	-1.2 (-2.0 to -0.4), BMI
Weight	1 (30)	0.00 (-0.39 to 0.39; p = 1.0; I ² = 71%)	0.0 kg (-8.0 to 8.0), kg
Waist	7 (424)	-0.25 (-0.41 to -0.10; p = 0.001; I ² = 49%)	-3.0 (-4.8 to -1.1) cm
Cholesterol	11 (642)	-0.50 (-0.70 to -0.31; p < 0.001; I ² = 76%)	-0.5 (-0.7 to -0.3) mmol/L
LDL	12 (674)	-0.54 (-0.67 to -0.40; p < 0.001; I ² = 61%)	-0.5 (-0.7 to -0.4) mmol/L
TRG	12 (686)	-0.32 (-0.54 to -0.10; p = 0.005; I ² = 82%)	-0.2 (-0.4 to -0.1) mmol/L
Glucose	11 (646)	-0.34 (-0.54 to -0.15; p < 0.001; I ² = 78%)	-0.2 (-0.4 to -0.1) mmol/L
HOMA-IR	10 (485)	-0.45 (-0.63 to -0.26; p < 0.001; I ² = 69%)	-0.9 (-1.3 to -0.5)
Insulin	9 (486)	-0.54 (-0.87 to -0.20; p = 0.006; I ² = 88%)	-9.1 (-13.2 to -5.1) pmol/L
HbA1c	3 (110)	-0.36 (-0.64 to -0.08; p = 0.01; I ² = 67%)	-3.5 (-6.7 to -0.3) mmol/mol
Testosterone	4 (188)	1.18 (-0.70 to 1.66; p < 0.001; I ² = 77%)	6.5 (2.0 to 7.4) nmol/L
Estrogen	1 (16)	0.32 (-0.07 to 0.71; p = 0.11)	20.2 (-4.0 to 44.4) ng/ml
Estradiol	2 (72)	0.89 (-0.77 to 2.54; p = 0.29; I ² = 96%)	17.8 (-15.4 to 50.0) pg/ml
FSH	3 (198)	0.20 (0.05 to 0.36; p = 0.01; I ² = 0%)	0.5 (0.1 to 0.9) IU/L
LH	3 (198)	0.20 (0.02 to 0.38; p = 0.03; I ² = 23%)	0.5 (0.2 to 0.9) IU/L
hsCRP	4 (132)	-0.31 (-0.62 to -0.004; p = 0.05; I ² = 60%)	-1.0 (-1.4 to -0.5) mg/L
Systolic BP	2 (36)	-0.12 (-0.37 to 0.14; p = 0.36; I ² = 0%)	-2.1 (-6.4 to 2.1) mmHg
Diastolic BP	2 (36)	-0.01 (-0.26 to 0.25; p = 0.97; I ² = 0%)	-0.2 (-2.9 to 3.2) mmHg